| 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer C Kratochwil, P Flechsig, T Lindner, L Abderrahim, A Altmann, W Mier, ... Journal of Nuclear Medicine 60 (6), 801-805, 2019 | 1215 | 2019 |
| The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer A Afshar-Oromieh, E Avtzi, FL Giesel, T Holland-Letz, HG Linhart, M Eder, ... European journal of nuclear medicine and molecular imaging 42, 197-209, 2015 | 1146 | 2015 |
| Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer A Afshar-Oromieh, CM Zechmann, A Malcher, M Eder, M Eisenhut, ... European journal of nuclear medicine and molecular imaging 41, 11-20, 2014 | 1097 | 2014 |
| 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer C Kratochwil, F Bruchertseifer, FL Giesel, M Weis, FA Verburg, F Mottaghy, ... Journal of Nuclear Medicine 57 (12), 1941-1944, 2016 | 1083 | 2016 |
| PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions A Afshar-Oromieh, A Malcher, M Eder, M Eisenhut, HG Linhart, ... European journal of nuclear medicine and molecular imaging 40, 486-495, 2013 | 1075 | 2013 |
| 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging M Eder, M Schäfer, U Bauder-Wüst, WE Hull, C Wängler, W Mier, ... Bioconjugate chemistry 23 (4), 688-697, 2012 | 1025 | 2012 |
| German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients K Rahbar, H Ahmadzadehfar, C Kratochwil, U Haberkorn, M Schäfers, ... Journal of Nuclear Medicine 58 (1), 85-90, 2017 | 907 | 2017 |
| 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 WP Fendler, M Eiber, M Beheshti, J Bomanji, F Ceci, S Cho, F Giesel, ... European journal of nuclear medicine and molecular imaging 44, 1014-1024, 2017 | 824 | 2017 |
| Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein T Lindner, A Loktev, A Altmann, F Giesel, C Kratochwil, J Debus, D Jäger, ... Journal of Nuclear Medicine 59 (9), 1415-1422, 2018 | 756 | 2018 |
| PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617 C Kratochwil, FL Giesel, M Stefanova, M Benešová, M Bronzel, ... Journal of Nuclear Medicine 57 (8), 1170-1176, 2016 | 691 | 2016 |
| Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient A Sartorius, KL Kiening, P Kirsch, CC von Gall, U Haberkorn, ... Biological psychiatry 67 (2), e9-e11, 2010 | 667 | 2010 |
| Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer M Benešová, M Schäfer, U Bauder-Wüst, A Afshar-Oromieh, C Kratochwil, ... Journal of Nuclear Medicine 56 (6), 914-920, 2015 | 653 | 2015 |
| F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients FL Giesel, B Hadaschik, J Cardinale, J Radtke, M Vinsensia, W Lehnert, ... European journal of nuclear medicine and molecular imaging 44, 678-688, 2017 | 621 | 2017 |
| Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours I Buchmann, M Henze, S Engelbrecht, M Eisenhut, A Runz, M Schäfer, ... European journal of nuclear medicine and molecular imaging 34, 1617-1626, 2007 | 620 | 2007 |
| A tumor-imaging method targeting cancer-associated fibroblasts A Loktev, T Lindner, W Mier, J Debus, A Altmann, D Jäger, F Giesel, ... Journal of Nuclear Medicine 59 (9), 1423-1429, 2018 | 617 | 2018 |
| Performance evaluation of a whole-body PET scanner using the NEMA protocol G Brix, J Zaers, LE Adam, ME Bellemann, H Ostertag, H Trojan, ... Journal of Nuclear Medicine 38 (10), 1614-1623, 1997 | 601 | 1997 |
| 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers FL Giesel, C Kratochwil, T Lindner, MM Marschalek, A Loktev, W Lehnert, ... Journal of Nuclear Medicine 60 (3), 386-392, 2019 | 591 | 2019 |
| Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy A Bierhaus, T Fleming, S Stoyanov, A Leffler, A Babes, C Neacsu, ... Nature medicine 18 (6), 926-933, 2012 | 571 | 2012 |
| Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients A Afshar-Oromieh, T Holland-Letz, FL Giesel, C Kratochwil, W Mier, ... European journal of nuclear medicine and molecular imaging 44, 1258-1268, 2017 | 566 | 2017 |
| Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer M Eder, O Neels, M Müller, U Bauder-Wüst, Y Remde, M Schäfer, ... Pharmaceuticals 7 (7), 779-796, 2014 | 472 | 2014 |
